JP2007534743A - アジュバント組成物およびその使用方法 - Google Patents

アジュバント組成物およびその使用方法 Download PDF

Info

Publication number
JP2007534743A
JP2007534743A JP2007510157A JP2007510157A JP2007534743A JP 2007534743 A JP2007534743 A JP 2007534743A JP 2007510157 A JP2007510157 A JP 2007510157A JP 2007510157 A JP2007510157 A JP 2007510157A JP 2007534743 A JP2007534743 A JP 2007534743A
Authority
JP
Japan
Prior art keywords
antigen
cell activator
vaccine
virus
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007510157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534743A5 (enExample
Inventor
ティオリエ,ジェローム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2007534743A publication Critical patent/JP2007534743A/ja
Publication of JP2007534743A5 publication Critical patent/JP2007534743A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2007510157A 2004-04-26 2005-04-25 アジュバント組成物およびその使用方法 Withdrawn JP2007534743A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56495904P 2004-04-26 2004-04-26
US62906904P 2004-11-18 2004-11-18
PCT/IB2005/001485 WO2005102385A1 (en) 2004-04-26 2005-04-25 Adjuvant composition and methods for its use

Publications (2)

Publication Number Publication Date
JP2007534743A true JP2007534743A (ja) 2007-11-29
JP2007534743A5 JP2007534743A5 (enExample) 2008-06-19

Family

ID=34969994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510157A Withdrawn JP2007534743A (ja) 2004-04-26 2005-04-25 アジュバント組成物およびその使用方法

Country Status (8)

Country Link
US (1) US20070218086A1 (enExample)
EP (1) EP1761278B1 (enExample)
JP (1) JP2007534743A (enExample)
AT (1) ATE419008T1 (enExample)
AU (1) AU2005235271A1 (enExample)
CA (1) CA2564562A1 (enExample)
DE (1) DE602005012097D1 (enExample)
WO (1) WO2005102385A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527404A (ja) * 2020-06-26 2023-06-28 リパブリック オブ コリア(アニマル アンド プラント クオレンティン エージェンシー) 新規な免疫増強剤及びこれを含むワクチン組成物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
CN101146575A (zh) * 2005-03-22 2008-03-19 依奈特制药公司 新类型的γδT细胞活化剂及其应用
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
ITMI20060366A1 (it) * 2006-03-01 2007-09-02 C4T S C A R L Composti organo tiopirosfosfati metodo per prepararli e composizioni che li contengono
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
GB2453475B (en) * 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
EP2324040B1 (en) 2008-09-10 2014-01-01 Innate Pharma Novel polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same
JP5676452B2 (ja) * 2008-09-29 2015-02-25 カディラ ファーマシューティカルズ リミテッド ワクチンアジュバント
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
AU2014233424B2 (en) * 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
KR102451441B1 (ko) * 2020-06-25 2022-10-12 대한민국 신규 면역증강제 및 이를 포함하는 백신 조성물
US20240261426A1 (en) * 2021-06-28 2024-08-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
GB202114311D0 (en) * 2021-10-06 2021-11-17 Molecular Attraction Ab New compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
BE1011282A3 (fr) * 1997-07-14 1999-07-06 Solvay Composition a base de polyethylene et procede de fabrication d'objets faconnes a partir de la composition.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
CA2453817C (en) 2001-07-20 2011-09-20 Bioagency Ag Organophosphorus compounds for the activation of gamma/delta t-cells
WO2003009812A2 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
FR2833266B1 (fr) 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
EP1426052B1 (en) 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
US7767842B2 (en) 2002-12-02 2010-08-03 Innate Pharma Sa Class of γδ T cells activators and use thereof
US20070025960A1 (en) * 2003-05-16 2007-02-01 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527404A (ja) * 2020-06-26 2023-06-28 リパブリック オブ コリア(アニマル アンド プラント クオレンティン エージェンシー) 新規な免疫増強剤及びこれを含むワクチン組成物
JP7575492B2 (ja) 2020-06-26 2024-10-29 リパブリック オブ コリア(アニマル アンド プラント クオレンティン エージェンシー) 新規な免疫増強剤及びこれを含むワクチン組成物

Also Published As

Publication number Publication date
CA2564562A1 (en) 2005-11-03
US20070218086A1 (en) 2007-09-20
DE602005012097D1 (de) 2009-02-12
ATE419008T1 (de) 2009-01-15
EP1761278B1 (en) 2008-12-31
WO2005102385A1 (en) 2005-11-03
AU2005235271A1 (en) 2005-11-03
EP1761278A1 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
JP2007534743A (ja) アジュバント組成物およびその使用方法
Cui et al. Flagellin as a vaccine adjuvant
Fraser et al. Improving vaccines by incorporating immunological coadjuvants
US11787842B2 (en) Tuberculosis compositions and methods of using the same
KR102389489B1 (ko) Hiv 백신 제형
JP5230780B2 (ja) アジュバント混合製剤
KR100764678B1 (ko) 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
JP2017530114A (ja) フラジェリンをコードする組み換えmvaによる鼻腔内免疫のための方法と組成物
Wang et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice
Ashhurst et al. Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against Mycobacterium tuberculosis
EP2303324A1 (en) Immunogenic composition
WO2020118159A1 (en) Methods and compositions comprising an nfkb inhibitor and an adjuvant
WO2005077411A2 (en) Composition and method for the treatment of carcinoma
JP2021512950A (ja) 新規なワクチンの免疫補助剤
Wang et al. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes
Torréns et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors
WO2006067635A2 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
Yazdanian et al. Immunization of mice by BCG formulated HCV core protein elicited higher th1-oriented responses compared to pluronic-F127 copolymer
US20060165687A1 (en) Vaccine adjuvant
US20080085261A1 (en) Vaccine Adjuvant
US20090087456A1 (en) Adjuvanted vaccine
EP2683388A2 (en) Vaccine formulation of mannose coated peptide particles
US20110262526A1 (en) Method of inducing an anti-viral immune response
US20050037015A1 (en) Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
KR20170132202A (ko) Isg15 및 어쥬번트로써의 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080423

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101221